Sarilumab use in severe SARS-CoV-2 pneumonia

BACKGROUND: Interleukin-6 signal blockade showed preliminary beneficial effects in treating inflammatory response against SARS-CoV-2 leading to severe respiratory distress. Herein we describe the outcomes of off-label intravenous use of Sarilumab in severe SARS-CoV-2-related pneumonia. METHODS: 53 p...

Descripción completa

Detalles Bibliográficos
Autores principales: Gremese, Elisa, Cingolani, Antonella, Bosello, Silvia Laura, Alivernini, Stefano, Tolusso, Barbara, Perniola, Simone, Landi, Francesco, Pompili, Maurizio, Murri, Rita, Santoliquido, Angelo, Garcovich, Matteo, Sali, Michela, De Pascale, Gennaro, Gabrielli, Maurizio, Biscetti, Federico, Montalto, Massimo, Tosoni, Alberto, Gambassi, Giovanni, Rapaccini, Gian Ludovico, Iaconelli, Amerigo, Zileri Del Verme, Lorenzo, Petricca, Luca, Fedele, Anna Laura, Lizzio, Marco Maria, Tamburrini, Enrica, Natalello, Gerlando, Gigante, Laura, Bruno, Dario, Verardi, Lucrezia, Taddei, Eleonora, Calabrese, Angelo, Lombardi, Francesco, Bernabei, Roberto, Cauda, Roberto, Franceschi, Francesco, Landolfi, Raffaele, Richeldi, Luca, Sanguinetti, Maurizio, Fantoni, Massimo, Antonelli, Massimo, Gasbarrini, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531933/
https://www.ncbi.nlm.nih.gov/pubmed/33043284
http://dx.doi.org/10.1016/j.eclinm.2020.100553

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531933/
https://www.ncbi.nlm.nih.gov/pubmed/33043284
http://dx.doi.org/10.1016/j.eclinm.2020.100553

Ejemplares similares